Filing Details

Accession Number:
0001179110-22-000693
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-01 21:18:29
Reporting Period:
2022-01-29
Accepted Time:
2022-02-01 21:18:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1709401 Rubius Therapeutics Inc. RUBY Biological Products, (No Disgnostic Substances) (2836) 042688109
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1800952 A. Laurence Turka C/O Rubius Therapeutics, Inc.
399 Binney Street, Suite 300
Cambridge MA 02139
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-29 7,438 $0.00 7,438 No 4 M Direct
Common Stock Disposition 2022-02-01 2,517 $6.57 4,921 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-01-29 7,438 $0.00 7,438 $0.00
Common Stock Stock Option (Right to Buy) Acquisiton 2022-01-31 143,750 $0.00 143,750 $6.75
Common Stock Restricted Stock Units Acquisiton 2022-01-31 34,500 $0.00 34,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
22,312 No 4 M Direct
143,750 2032-01-30 No 4 A Direct
34,500 No 4 A Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
  2. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units listed in Table II. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.57 to $6.70, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The shares underlying the restricted stock units vest in four equal annual installments beginning on January 29, 2022.
  5. 25% of this option shall vest on January 31, 2023, then in 12 equal quarterly installments thereafter.
  6. The shares underlying the restricted stock units vest in four equal annual installments beginning on January 31, 2023.